About A public-private partnership that supports the discovery of new medicines through open access research. Mission and Philosophy Partners Governance Collaborators Laboratories Key Achievements Research Collaborations and Communications Why Companies Enter Open Science Partnerships with SGC SGC Open Science Policy Equity, Diversity and Inclusion FAQs Science TARGET ENABLING PACKAGES (TEPs) TISSUE PLATFORM PROTEIN STRUCTURES PUBLICATIONS CHEMICAL PROBES Donated chemical probes Biological probes Human Kinase Chemical Probe Program Probes against other protein classes RECOMBINANT ANTIBODIES Structure-guided Drug Discovery Coalition (SDDC) SDDC Publications CREATE ChemNET Research Program Trainees Open Access Learning Impact Faculty & Industry Participants Structural & Chemical Biology Bootcamp Events Structural Biology Programme Structural Parasitology Rare Diseases Genome Integrity and Neurodegeneration Growth Factor Signalling Integral Membrane Proteins Metabolic Enzymes Phosphorylation-Dependent Signalling Protein Kinases Ubiquitin Biology Chemical Biology Antibodies Protein Families Methyl Lysine Readers Histone Deacetylases Histone Acetyltransferases Demethylases Bromodomains Protein Methyltransferases Probe Development Screening Platforms Epigenetic Cell Assays Fragment Based Screening Informatics Medicinal Chemistry ChromoHub Phylogenetic Trees UbiHub Phylogenetic Trees Histone Tails Epigenetics Pocketome Technological Science Biotechnology Biophysics Screening Platforms Research Informatics Protein Crystallography Medicinal Chemistry Reagents & Resources Reagents Chemical Probes Antibodies SGC Vectors SGC Plasmids SGC Constructs Resources Structure Gallery Protein Production Protocols ChromoHub Phylogenetic Trees UbiHub Phylogenetic Trees Histone Tails Fragment Screening Crystal Forms Fragalysis MichaelaNGLo Technologies High Throughput Protein Crystallisation Lex Bubbling System Frapid People Global SGC Director Aled Edwards Susan McCormick Max Morgan Academic Collaborators Industrial/ SME collaborators Non-Scientists SGC OCN Mat Todd SGC Neuro Edward Fon Ziv Gan-Or Thomas Durcan Roxanne Lariviere Peter McPherson Jean-François Trempe Carl Laflamme Toronto Cheryl Arrowsmith Dalia Barsyte-Lovejoy Peter J. Brown Jinrong Min Takis Prinos Matthieu Schapira Masoud Vedadi Levon Halabelian Biotechnology Crystallography UNC Tim Willson Alison Axtman David Drewry Karolinska Michael Sundström Susanne Gräslund Louise Berg Per-Johan Jakobsson Frankfurt Stefan Knapp Susanne Müller-Knapp Apirat Chaikuad Thomas Hanke Vladimir Rogov Krishnal Saxena Andreas Joerger Václav Němec News & Outreach News & Events SGC News Symposia & Workshops Blog Press Releases Public Events Public Engagement SGC Languages General Public Open Lab Notebooks Schools Media Patient Groups Governments TOronto Ubiquitin Club And Network (TOUCAN) Careers Tweets by thesgconline
A public-private partnership that supports the discovery of new medicines through open access research.
PFI-6 A novel chemical probe for MLLT1/3The probe and control are available from Sigma. For any inquiries please contact proberequests@thesgc.org.group newOverview PFI-6 PFI-6N (Negative control) Increasing numbers of papers describing YEATS biology are emerging, and there is a growing need for high quality chemical probes that can be used to study YEATS domains. A collaboration between Pfizer and the SGC has resulted in the discovery of PFI-6, a potent inhibitor of MLLT1/3. PFI-6 has a unique chemotype relative to the current MLLT1/3 chemical probe NVS-MLLT-1. PFI-6N has also been developed as a structurally similar negative control compound. Properties Physical and chemical properties for PFI-6 Molecular weight 391.43 Molecular formula C22H21N3O4 IUPAC name (R0-N-(2,3-dihydro-1H-inden-1-yl)-5-(4-(dimethylcarbamoyl)-3-hydroxyphenyl)isoxazole-3-carboxamide MollogP 2.6 PSA 91.23 No. of chiral centres 0 No. of rotatable bonds 6 No. of hydrogen bond acceptors 7 No. of hydrogen bond donors 2 Storage store as a dry poweder or as DMSO stock solutions (10mM) at -20 °C Dissolution Soluble in DMSO up to 10mM Physical and chemical properties for PFI-6N Molecular weight 357.41 Molecular formula C19H23N3O4 IUPAC name N-cyclopentyl-5-(4-(dimethylcarbamoyl)-3-hydroxyphenyl)-N-methylisoxazole-3-carboxamide MollogP 1.86 PSA 82.44 No. of chiral centres 0 No. of rotatable bonds 6 No. of hydrogen bond acceptors 7 No. of hydrogen bond donors 1 Storage Store as a dry powder or as DMSO stock solutions (10mM) at -20 °C Dissolution Soluble in DMSO up to 10mM SMILES: PFI-6: O=C(N(C)C)C1=C(O)C=C(C2=CC(C(N[C@@H]3CCC4=C3C=CC=C4)=O)=NO2)C=C1 PFI-6N: O=C(N(C)C)C1=C(O)C=C(C2=CC(C(N(C)C3CCCC3)=O)=NO2)C=C1 InChI: PFI-6: 1S/C22H21N3O4/c1-25(2)22(28)16-9-7-14(11-19(16)26)20-12-18(24-29-20)21(27)23-17-10-8-13-5-3-4-6-15(13)17/h3-7,9,11-12,17,26H,8,10H2,1-2H3,(H,23,27)/t17-/m1/s1 PFI-6-N: 1S/C19H23N3O4/c1-21(2)18(24)14-9-8-12(10-16(14)23)17-11-15(20-26-17)19(25)22(3)13-6-4-5-7-13/h8-11,13,23H,4-7H2,1-3H3 InChIKey: PFI-6: IXWUILRSNIQHDM-QGZVFWFLSA-N PFI-6-N:CKEICVFLYGXFOP-UHFFFAOYSA-N Selectivity ProfilePFI-6 shows potent activity on MLLT1/3 (Table 1). PFI-6 is universally inactive in the SGC Bromodomain panel, and showed no activity in an Invitrogen panel of 40 kinases (screening conducted at 10µM). Additionally, PFI-6 showed no activity in a panel of 25 PDEs, ion channels and GPCRs >50µM. The negative control, PFI-6N, was not reactive against MLLT1 >30µM, MLLT3 >30µM, YEATS2 >30µM and YEATS4 >30µM. MLLT1 MLLT3 YEATS2 YEATS4 HTRF IC50 (µM) 0.14 0.16 >40 >40 BLI Kd (µM) 0.11 0.11 n.d. n.d. ITCKD (µM) 0.082 0.076 n.d. n.d. Tm Shift (°C) 3.61 5.13 0.00 -0.02 Table 1: Potency Against Target Family Figure 1: PFI-6 specfically inhibits MLLT1 and MLLT3. Cell-based Assay DataIn the NanoBRET cellular target engagement assay, PFI-6 displayed potent inhibition, with an average IC50 value of 0.76 μM (±0.1) (Figure 1). In comparison, PFI-6N had no inhibitory properties (up to 30 μM) (Figure 1). Further in cell validation using a Fluorescence Recovery After Photobleaching (FRAP) assay was used to confirm target inhibition by PFI-6 (Figure 2) . Figure 1: A NanoBRET assay was used to determine MLLT3 target engagement in cells. Figure 2: Confirmation of MLLT1 target engagement in cells by Fluorescence Recovery After Photobleaching analysis. Co-crystal structuresThe figure below shows PFI-6 is soaked into the YEATS domain. PDB codes will be added when they become available.